Anavex Life Sciences (AVXL) Net Income (2016 - 2025)
Anavex Life Sciences (AVXL) posted Net Income of -$2.6 billion for Q4 2025, up 93.57% sequentially from -$39.7 billion in Q3 2025, and down 2990.0% YoY from $88.4 million in Q4 2024.
Anavex Life Sciences (AVXL) Net Income (2016 - 2025) Analysis & Trends
Anavex Life Sciences has reported Net Income for 10 years, with the latest figure at -$2.6 billion in Q4 2025.
- Quarterly Net Income fell 2990.0% year-over-year to -$2.6 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$42.4 billion (down 36070.68% YoY) and the FY2025 annual result came in at -$39.8 billion, down 92377.13% from the prior year.
- Net Income rose to -$2.6 billion in Q4 2025 per AVXL's latest filing, from -$39.7 billion in the prior quarter.
- Over five years, Net Income peaked at -$8.2 million in Q1 2021 and troughed at -$39.7 billion in Q3 2025.
- A 5-year average of -$2.1 billion and a median of -$12.0 million in 2024 frame the typical range for Net Income.
- The sharpest annual moves came in 2023 and 2025: Net Income jumped 33.53% in 2023, then plunged 338170.2% in 2025.
- Over 5 years, Net Income stood at -$10.9 million in 2021, then retreated by 19.2% to -$13.0 million in 2022, then surged by 33.53% to -$8.6 million in 2023, then tumbled by 859.17% to -$82.7 million in 2024, then slumped by 2990.0% to -$2.6 billion in 2025.
- According to Business Quant data, Net Income over the past three periods registered -$2.6 billion, -$39.7 billion, and -$60.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - | -2.56 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.56 Bn |
| Sep 30, 2025 | -39.73 Bn |
| Jun 30, 2025 | -60.27 Mn |
| Mar 31, 2025 | -51.14 Mn |
| Dec 31, 2024 | -82.70 Mn |
| Sep 30, 2024 | -11.74 Mn |
| Jun 30, 2024 | -12.21 Mn |
| Mar 31, 2024 | -10.55 Mn |
| Dec 31, 2023 | -8.62 Mn |
| Sep 30, 2023 | -10.15 Mn |
| Jun 30, 2023 | -11.28 Mn |
| Mar 31, 2023 | -13.11 Mn |
| Dec 31, 2022 | -12.97 Mn |
| Sep 30, 2022 | -14.29 Mn |
| Jun 30, 2022 | -12.37 Mn |
| Mar 31, 2022 | -10.44 Mn |
| Dec 31, 2021 | -10.88 Mn |
| Sep 30, 2021 | -11.59 Mn |
| Jun 30, 2021 | -10.22 Mn |
| Mar 31, 2021 | -8.18 Mn |